Global API Intermediates Market, By Type (Veterinary Drug Intermediates, Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others) - Industry Trends and Forecast to 2030.
Global API Intermediates Market Analysis and Size
Active pharmaceutical ingredients are the substance or combination of substances intended to be used in the manufacturing of a drug product which when used in the production of the drug, becomes an active pharmaceutical ingredient. Such substances are used to provide pharmacological activity.
Data Bridge Market Research analyses that the global API intermediates market which was USD 2.34 billion in 2022, is expected to reach USD 5.67 billion by 2030, and is expected to undergo a CAGR of 7.10% during the forecast period of 2023-2030. “Pharmaceutical/bulk drug intermediates” dominates the type segment of the global API intermediates market owing to the rising pharmaceutical industries. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
API Intermediates Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Veterinary Drug Intermediates, Pharmaceutical / Bulk Drug Intermediates), Product (Bromo Compound, O-Benzyl Salbutamol, Hemisulfate, Oxirane, Bisoprolol Base, Chiral PCBHP, Pheniramine Base, Chlorpheniramine Base, Brompheniramine Base, Mepyramine/Pyrilamine Base, 6-Amino-1,3-Dimethyl Uracil, Theofylline, Acefylline, Xanthine, Nitriles, Others), Therapeutic Type (Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, Dermatology, Urology, Others), Customers (Direct Users/Pharma Companies, Traders/Wholesalers/Distributors, Associations/Govt. Institutions/Pvt Institutions), End User (API Manufacturer, Finished Product Manufacturer), Distribution Channel (Direct Tender, Retail Sales, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
When discussing medicines and chemical synthesis, the term "API intermediates" refers to the many chemical compounds and materials created throughout the lengthy process of synthesising an Active Pharmaceutical Ingredient (API). The active ingredients (APIs) of a medicine are those that give it its therapeutic action. The creation of APIs frequently entails a number of chemical reactions, purification procedures, and conversions of raw ingredients into the desired finished product. Various intermediate compounds are created throughout this process, each acting as a stepping stone towards the final API. These intermediaries might have unique chemical characteristics, structures, and applications.
Global API Intermediates Market Dynamics
Drivers
- Growing Pharmaceutical Industry
Due to factors like ageing populations, rising healthcare costs, and the demand for novel and creative treatments, the pharmaceutical business is still growing globally. This expansion fuels the need for API intermediates, which are crucial ingredients in the production of pharmaceuticals.
- Rising Technological Advancements
The efficiency and cost-effectiveness of the manufacturing of API intermediates are improved by developments in chemical synthesis and process technologies, thus fuelling market expansion.
- Increasing Demand of Biopharmaceuticals
The need for bioprocess intermediates has expanded as a result of the rise in biopharmaceuticals such recombinant proteins and monoclonal antibodies. These steps in the process are necessary to produce biologics, which is helping to drive market growth.
Opportunities
- Growing Demand of Personalized Medicine
The development of APIs and intermediates customised to particular patient profiles is required by the trend towards personalised medicine and targeted medicines, which can stimulate research and development in this field.
- Rising Collaboration and Partnerships
Innovative solutions and access to new markets can result from collaboration between API intermediate producers, pharmaceutical firms, and research organisations.
- Increasing Focus Towards Green and Sustainable Chemistry
There is a chance for API intermediate producers to create and deliver greener and more sustainable chemical processes and intermediates as sustainability and environmentally friendly practises receive increasing attention.
Restrains/ Challenges
- Strict Regulations
In the pharmaceutical sector, strict regulatory regulations can be a major barrier. It can be expensive and time-consuming to comply with and keep up with rules like Good Manufacturing Practises (GMP) and limit market growth.
- Supply Chain Disruptions
Due to the fact that many manufacturers rely on a complicated global network of suppliers for their raw materials and intermediates, the global API intermediates market is vulnerable to supply chain disruptions. The supply chain may be hampered by unforeseen circumstances like natural disasters or political unrest.
- Safety Concerns
A top priority is to ensure the security of industrial procedures and the safety of employees. Hazardous substances and reactions can be used in the chemical synthesis process.
- High Costs
The cost-effectiveness and supply chain stability of the manufacturing of API intermediates can be affected by changes in the prices and availability of raw materials and chemicals.
This global API intermediates market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global API intermediates market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global API Intermediates Market Scope
The global API intermediates market is segmented on the basis of the type, product, therapeutic class, customers, end users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Veterinary Drug Intermediates
- Pharmaceutical / Bulk Drug Intermediates
Product
- Bromo Compound
- O-Benzyl Salbutamol
- Hemisulfate
- Oxirane
- Bisoprolol Base
- Chiral PCBHP
- Pheniramine Base
- Chlorpheniramine Base
- Brompheniramine Base
- Mepyramine/pyrilamine Base
- 6-Amino-1,3-Dimethyl Uracil
- Theofylline
- Acefylline
- Xanthine
- Nitriles
- Others
Therapeutic Type
- Autoimmune Diseases
- Oncology
- Metabolic Diseases
- Ophthalmology
- Cardiovascular Diseases
- Infectious Diseases
- Neurology
- Respiratory Disorders
- Dermatology
- Urology
- Others
Customers
- Direct Users/Pharma Companies
- Traders/Wholesalers/Distributors
- Associations/Govt. Institutions/Pvt Institutions
End Users
- API Manufacturer
- Finished Product Manufacturer
Distribution channel
- Direct Tender
- Retail Sales
- Others
Global API Intermediates Market Regional Analysis/Insights
Global API intermediates market is analyzed and market size information is provided on the basis of the country, type, product, therapeutic type, customers, end user and distribution channel as referenced above.
The countries covered in the global API intermediates market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa.
North America is dominating in the global API intermediates market and is expected to grow with the highest growth rate in the forecast period of 2023 to 2030 because of increasing healthcare expenditure and well-established healthcare infrastructure for the pharmaceutical / bulk drug intermediates segment.
Asia Pacific is leading the growth of the global API intermediates market and pharmaceutical / bulk drug intermediates segment is dominating in the country due to increase in availability of API intermediates at lower cost. The pharmaceutical / bulk drug intermediates segment in Germany is dominating in the global API intermediates market owing to increasing consumption demand for the API intermediates.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
Global API intermediates market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period 2023-2030.
Competitive Landscape and API intermediates market Share Analysis
The global API intermediates market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to global API intermediates market.
Some of the major players operating in the global API intermediates market are:
- HIKAL Ltd. (India)
- Cambrex Corporation (U.S.)
- Ganesh-Group, AlzChem Group AG (India)
- Vasudha Pharma (India)
- Anyang General Chemical Co.,Ltd. (China)
- Sarex (India)
- Sandoo Pharmaceuticals and Chemicals Co., Ltd (India)
- Atul Ltd (India)
- Sandoz International GmbH (a subsidiary of Novartis AG) (Germany)
- Aceto (U.S.)
- Supriya Lifescience Ltd. (India)
- LEVACHEM COMPANY LIMITED (China)
- Vertellus (U.S.)
- Dishman Carbogen Amcis Ltd (India)
- Sanofi (France)
- Divi's Laboratories Limited (India)
- AARTI INDUSTRIES LIMITED (India)
- Aurobindo Pharma (India)
- BASF SE (Germany)
SKU-